LSE:AZNPharmaceuticals
AstraZeneca Leans Into Oncology Obesity Drugs And China Growth Commitments
AstraZeneca received FDA Priority Review for DATROWAY for metastatic triple negative breast cancer.
The company announced an expanded obesity drug pipeline through a broad alliance with CSPC Pharmaceuticals.
AstraZeneca committed a planned £15b investment in manufacturing and R&D in China.
AstraZeneca (LSE:AZN) is drawing attention with this mix of oncology, obesity and China focused news, alongside a £141.04 share price and a 24.2% return over the past year. Over 5 years, the stock is up...